FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar

The agency approved a higher concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Medscape Medical News

source https://www.medscape.com/viewarticle/990154?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?